BSTG - Biostage, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
2.2900
-0.0600 (-2.55%)
At close: 1:53PM EDT
Stock chart is not supported by your current browser
Previous Close2.3500
Open2.3500
BidN/A x N/A
AskN/A x N/A
Day's Range2.2800 - 2.3500
52 Week Range0.7500 - 3.3000
Volume1,603
Avg. Volume1,917
Market Cap16.072M
Beta (3Y Monthly)2.72
PE Ratio (TTM)N/A
EPS (TTM)-1.3810
Earnings DateNov 6, 2019 - Nov 11, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Newsfile

    Biostage, Inc. Joins the Stock Day Podcast to Discuss Their Pending FDA Application

    Phoenix, Arizona--(Newsfile Corp. - September 3, 2019) - The Stock Day Podcast welcomed Jim McGorry of Biostage, Inc. (OTCQB: BSTG) ("the Company"), a biotechnology startup developing bioengineered organ implants based on its Cellspan technology that combines a proprietary biocompatible scaffold with a patient's own stem cells to create bioengineered organ implants. McGorry is the Company CEO and director, and was joined by Stock Day host Everett Jolly. Jolly began the interview by asking ...

  • Biostage Reports Second Quarter 2019 Financial Results
    PR Newswire

    Biostage Reports Second Quarter 2019 Financial Results

    -- Preparing to file first IND in September 2019 HOLLISTON, Mass. , Aug. 13, 2019 /PRNewswire/ -- Biostage, Inc.  (OTCQB: BSTG) ("Biostage" or the "Company"), a biotechnology company ...

  • Biostage to Host Conference Call to Discuss Second Quarter 2019 Financial Results and Business Update
    PR Newswire

    Biostage to Host Conference Call to Discuss Second Quarter 2019 Financial Results and Business Update

    HOLLISTON, Mass., Aug. 7, 2019 /PRNewswire/ -- Biostage, Inc. (BSTG), a biotechnology company developing bioengineered organ implants to treat life-threatening conditions of the esophagus, bronchus and trachea, announced today that it will report its financial results for the three and six months ended June 30, 2019 in a press release that will be issued pre-market on Tuesday August 13, 2019. Biostage management also announced that it will host a conference call with a live audio webcast that same day at 9:00 AM ET to review its operational progress and financial report. The live audio webcast will be accessible on the Events page of the Investors section on the Company's website at www.biostage.com and will be archived for 60 days.

  • Biostage Reports First Quarter 2019 Financial Results
    PR Newswire

    Biostage Reports First Quarter 2019 Financial Results

    - Preparing to file first IND in Q3 2019 HOLLISTON, Mass. , May 14, 2019 /PRNewswire/ --  Biostage, Inc.  (OTCQB: BSTG) ("Biostage" or the "Company"), a biotechnology company developing ...

  • ACCESSWIRE

    Biostage, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / May, 14, 2019 / Biostage, Inc. (OTCQB: BSTG ) will be discussing their earnings results in their 2019 First Quarter Earnings to be held on May, 14, 2019 at 9:00 AM Eastern Time. ...

  • Biostage to Host Conference Call to Discuss First Quarter 2019 Financial Results and Business Update
    PR Newswire

    Biostage to Host Conference Call to Discuss First Quarter 2019 Financial Results and Business Update

    HOLLISTON, Mass., May 8, 2019 /PRNewswire/ -- Biostage, Inc. (BSTG), a biotechnology company developing bioengineered organ implants to treat life-threatening conditions of the esophagus, bronchus and trachea, announced today that it will report its financial results for the three months ended March 31, 2019 in a press release that will be issued pre-market on Tuesday May 14, 2019.  Biostage management also announced that it will host a conference call with a live audio webcast that same day at 9:00 AM ET to review its operational progress and financial report. The live webcast will be accessible on the Events page of the Investors section on the Company's website at www.biostage.com, and will be archived for 60 days. Biostage is a biotechnology company developing bioengineered organ implants based on the Company's Cellframe™ technology which combines a proprietary biocompatible scaffold with a patient's own stem cells to stimulate tissue regeneration in certain organs.

  • Biostage Reports 2018 Financial Results
    PR Newswire

    Biostage Reports 2018 Financial Results

    - Pre-clinical and human compassionate use clinical evidence support IND filing mid-year 2019 HOLLISTON, Mass. , March 28, 2019 /PRNewswire/ --  Biostage, Inc.  (OTCQB: BSTG) ("Biostage" or the ...

  • Biostage to Host Conference Call to Discuss 2018 Financial Results and Business Update
    PR Newswire

    Biostage to Host Conference Call to Discuss 2018 Financial Results and Business Update

    HOLLISTON, Mass., March 21, 2019 /PRNewswire/ -- Biostage, Inc. (BSTG), a biotechnology company developing bioengineered organ implants to treat life-threatening conditions of the esophagus, bronchus and trachea, announced today that it will report its financial results for the quarter and year ended December 31, 2018 in a press release that will be issued pre-market on Thursday March 28, 2019.  Biostage management also announced that it will host a conference call with a live audio webcast that same day at 9:00 AM ET to review its operational progress and financial report. The live webcast will be accessible on the Events page of the Investors section on the Company's website at www.biostage.com, and will be archived for 60 days. Biostage is a biotechnology company developing bioengineered organ implants based on the Company's Cellframe™ technology which combines a proprietary biocompatible scaffold with a patient's own stem cells to stimulate tissue regeneration in certain organs.

  • First-In-Human Case Using Biostage's Bioengineered Esophageal Implant is Presented at Major Surgical Meeting
    PR Newswire

    First-In-Human Case Using Biostage's Bioengineered Esophageal Implant is Presented at Major Surgical Meeting

    HOLLISTON, Mass., Jan. 28, 2019 /PRNewswire/ -- Dennis Wigle, M.D., Ph.D, chair of thoracic surgery at Mayo Clinic in Rochester, Minnesota, speaking at the Society of Thoracic Surgeons Tech-Con 2019 meeting on January 26, announced for the first time the details of a single-patient case report that describes the use of new technology to repair the patient's esophagus following esophageal reconstruction associated with the removal of a tumor mass in the chest. The technology being developed by Biostage, Inc. (BSTG), the Cellspan™ Esophageal Implant product candidate (CEI), uses a synthetic tubular scaffold seeded with the patient's stem cells to repair and restore a living biologic conduit. This milestone advancement demonstrated that segmental esophageal reconstruction using a stem cell-coated implant can facilitate reconstruction, regrowth and regeneration of a gastrointestinal tissue in a human patient.

  • Mr. Matthew Dallas and Mr. Jeffrey Young Appointed to Biostage Board of Directors
    PR Newswire

    Mr. Matthew Dallas and Mr. Jeffrey Young Appointed to Biostage Board of Directors

    HOLLISTON, Mass., Nov. 8, 2018 /PRNewswire/ -- Biostage, Inc. (BSTG), a biotechnology company developing bioengineered organ implants to treat life-threatening conditions of the esophagus, bronchus and trachea, today announced that Mr. Matthew Dallas and Mr. Jeffrey Young were appointed to its Board of Directors, effective November 6, 2018. Mr. Dallas brings more than 20 years of financial management experience, including 18 years in the life sciences industry. Prior to AVEO, Mr. Dallas served as CFO and Treasurer of CoLucid Pharmaceuticals, a position he held through that biopharmaceutical company's initial public offering, follow-on offering, and subsequent acquisition for approximately $960 million by Eli Lilly and Company in March 2017.

  • Biostage Reports 2018 Third Quarter Financial Results
    PR Newswire

    Biostage Reports 2018 Third Quarter Financial Results

    - Scientific feedback along with new and consistent data continue to validate technology - Ongoing studies support mid-year 2019 filing of IND HOLLISTON, Mass. , Nov. 8, 2018 /PRNewswire/ --  Biostage, ...

  • PR Newswire

    Ms. Ting Li Appointed to Biostage Board of Directors

    HOLLISTON, Mass., Nov. 7, 2018 /PRNewswire/ -- Biostage, Inc. (BSTG), a biotechnology company developing bioengineered organ implants to treat life-threatening conditions of the esophagus, bronchus, and trachea, today announced appointing Ms. Ting Li to its Board of Directors after her valuable role this year in securing funding for the Company, effective November 6, 2018. Ms. Li brings over 20 years of investment banking experience, building relationships between customers and enterprises. Ms. Li is currently a managing partner at Donghai Securities Co., Ltd, a top asset management company in China, and also serves as the Vice President of the Jilin Enterprise Chamber of Commerce and advisor of the School of Continuing Education of Tsinghua University.

  • PR Newswire

    Biostage awarded $1.1 million Phase II NIH SBIR Fast-Track grant to develop Cellspan™ Esophageal Implant (CEI) as a novel treatment for pediatric esophageal atresia

    HOLLISTON, Mass., Nov. 6­­­, 2018 /PRNewswire/ -- Biostage, Inc. (BSTG), a biotechnology company developing bioengineered organ implants to treat life-threatening conditions of the esophagus, bronchus and trachea, today announced it has been awarded $1.1 million from Phase II of its previously-announced Fast-Track Small Business Innovation Research (SBIR) grant by the Eunice Kennedy Shriver National Institute of Child Health and Human Development of the National Institutes of Health. The grant funding will support Biostage's development and testing of its Cellspan™ Esophageal Implant (CEI) for treatment of neonatal esophageal atresia. Biostage's Sumati Sundaram, PhD and Christine Finck, MD, FACS, and Surgeon-In-Chief at Connecticut Children's Medical Center are the principle investigators on this grant.

  • Biostage to Host Conference Call to Discuss Third Quarter 2018 Financial Results and Operations
    PR Newswire

    Biostage to Host Conference Call to Discuss Third Quarter 2018 Financial Results and Operations

    Biostage is a biotechnology company developing bioengineered organ implants based on the Company's Cellframe™ technology which combines a proprietary biocompatible scaffold with a patient's own stem cells to stimulate tissue regeneration in certain organs. Cellspan™ implants are being developed to treat life-threatening conditions of the esophagus, bronchus or trachea with the hope of dramatically improving the treatment paradigm for patients.